Profile data is unavailable for this security.
About the company
Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
- Revenue in -- (TTM)--
- Net income in --
- Incorporated2013
- Employees--
- LocationAbivax SA7-11 Boulevard HaussmannPARIS 75009FranceFRA
- Phone+33 153830963
- Fax+33 494279261
- Websitehttps://www.abivax.com/
More ▼
34.64%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Invus Public Equities Advisors LLCas of 29 Feb 2024 | 5.57m | 8.85% |
| Deep Track Capital LPas of 31 Dec 2023 | 4.30m | 6.83% |
| Blackstone Alternative Asset Management LPas of 31 Dec 2023 | 2.37m | 3.77% |
| Cormorant Asset Management LPas of 31 Dec 2023 | 2.13m | 3.39% |
| Commodore Capital LPas of 31 Dec 2023 | 1.90m | 3.01% |
| Great Point Partners LLCas of 31 Dec 2023 | 1.55m | 2.46% |
| Franklin Advisers, Inc.as of 31 Dec 2023 | 1.25m | 1.99% |
| Nantahala Capital Management LLCas of 31 Dec 2023 | 1.01m | 1.61% |
| VHCP Management LLCas of 31 Dec 2023 | 998.57k | 1.59% |
| Janus Henderson Investors US LLCas of 31 Dec 2023 | 720.43k | 1.15% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
